Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia

To the editor: Descriptions of chromosomally abnormal Philadelphia-negative (Ph−) clones in chronic myeloid leukemia (CML) patients treated with chemotherapy,[1][1] interferon-alpha,[2][2] and, most recently, imatinib[3][3],[4][4] suggest that such events arise indirectly as a result of